P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
JOURNAL OF THORACIC ONCOLOGY（2018）
关键词
Real life study,Immunotherapy,progression
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要